LAUSR

Subarachnoid haemorrhage (SAH) accounts for 5% of all strokes. Estimations suggest fatality rates of ~30% and about 20% rates of functional dependency, with major impact on years of life lost1 . Intracranial hypertension (defined as an intracranial pressure >20 mm Hg) occurs in up to 50% of patients with SAH, during at acute (<24 hours), subacute (up to 7-10 days), and late (after 10 days) stages. This frequent complication contributes to secondary brain injury and independently predicts unfavorable outcome. Up to date, treating intracranial hypertension still represents a major therapeutic target for improving outcome in patients with SAH3 .